Gesynta Pharma develops pharmaceutical treatments targeting chronic inflammation in a wide range of diseases

Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and pain, thereby providing safe and efficacious treatments for several serious diseases. Based on research originating from Karolinska Institutet, the company has advanced a portfolio of drug candidates with a unique and validated mechanism of action and is thereby well-positioned to deliver both patient and shareholder value.
Read more about our development projects

Experienced leadership

Gesynta Pharma’s management and board of directors have experience from senior positions in leading pharmaceutical companies, bringing deep knowledge from all drug development phases – from discovery to the commercialization of approved products.

Executive Team Board

Strong investor base

The company’s major shareholders include the reputable institutional investors Hadean Ventures, Industrifonden and Linc, as well as successful life science industry entrepreneurs.

Our lead candidate: vipoglanstat

Vipoglanstat (GS-248) is a non-hormonal, potentially disease-modifying drug candidate that inhibits the inflammation-related enzyme mPGES-1. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and beneficial pharmacological properties. Based on these results and robust data from a preclinical proof-of-concept study in an advanced disease model of endometriosis, vipoglanstat is expected to enter a phase II clinical trial in patients with endometriosis in 2024.

Read more

Second-generation drug candidates

Gesynta Pharma’s pipeline presents a broad range of opportunities based on unique anti-inflammatory and pain-relieving properties. The first compound in this new generation of drug candidates, GS-073, is ready to enter clinical phase I.

Read more

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.